Member Info for tomhuk2000

Hi Oppenheimer,

As yet it’s hard to confirm the veracity of the 156p broker note from “Logic”

Might be best to stick with the confirmed Berenberg 120p from November. They should be issuing a new updated one since the study results and contract win IMO .

I’m yet to see the recorded presentation, but a good friend of mine and a big biotech investor was there in Mayfair last night and relayed that the big reassurances he took away were that there wouldn’t be a placing anytime soon as their “aim is to be cash positive way before that’s needed”. Good sign.

He also stated that they key takeaway was they are singularly focussed on marketing and commercialisation of their product offering. Good head of steam built up and very much on the front foot.

I’ll upload the link to the presentation as and when it goes live

And if he’d written just “Breakthrough” then you’d have probably pulled him up on it as more unsubstantiated hype/bluster. Damned if he does and damned if he doesn’t Bantham. Deary me.

Hi NikNak,

Well, as I’ve said several times on here, I’ve been observing AGL for a while but only felt comfortable buying in around late November because of ANGLE’s efforts to make the product service offering more commercially accessible/viable. That’s what has held it back from getting significant deals over the line since FDA approval.

For me I’d like to see:

- Results of the Ovarian and Prostate Studies

- Other outstanding third party molecular results

- Existing deals/contracts being converted into repeat business but in a more expansive profitable way - For example: The recent Eisai pilot study being a success and converted into a bigger contract across the broader Eisai research platform.

- More contract wins. Ideally with company’s even larger than the $14bn MCAP Eisai.

- More TR1’s from institutional investors

Not essential but would be nice:

- Director buys when out of closed periods.

Overall I’m greatly encouraged by the last few months activities and, now the tech is better placed for market, AGL seem to be on the front foot with regard to commercialisation and bringing in significant revenue.

A mention here for ANGLE with regards to ovarian cancer research/diagnosis:

"ANGLE Plc’s Parsortix platform, presents an innovative approach to detection, providing analysis of circulating tumour cells. This platform has demonstrated clinical validity and has previously been approved for Metastatic Breast Cancer (‘Transforming cancer care with the first FDA cleared medical device for the capture and harvest of circulating tumor cells’, 2022). This novel liquid biopsy platform holds the potential to enable earlier OC diagnosis, ultimately improving patient survival rates."

https://medium.com/@isabelle.ferenczi/the-future-of-targeted-treatments-for-ovarian-cancer-4e14b9237da7

SonnyCher

The AGL @proactive one2one forum is on from 6pm until 9pm and is a live event in Mayfair, London.

It will be recorded and go live soon after I believe.

Hi Bantham,

As yet no one has asked me to do so and sadly with what I’ve seen of this board it doesn’t seem to merit much beyond what I’ve already posted.

But I have shared in the past weeks my take on why I’m invested (the last 12 months worth of endeavours to make the product offering more commercially viable and ramp up in marketing activity ), also my opinions on past cash burn and why it’ll be lower in 2024 and my opinions re being funded to Q2 2025.

Even posting my message this morning alerting the group to AGL’s attendance at this months DDR summit in Boston was met with a “why is this relevant” comment. (Anything in the least bit positive, even an official date in the diary is met with derision)

Up until this evening I have been polite and understanding to all on this BB who have differed with my opinions on Angle. I think that, to quote my post earlier about Newland being damned if he does and damned if he doesn’t re tonight’s presentation, anything I put forward will be disregarded.

It’s a sad state of affairs when after 6 weeks of being civil and open minded a legitimate investor is so disappointed in the dross and overall closed minded approach from users of this board, that he sees no value in being a part of it. (But maybe that’s the aim of certain posters on here?)

That’s your most positive post for month FeverTree. Feels good huh?

i’ve always been as polite as possible when chatting with you fevertree, but if that’s how you want to be….

it seems utterly moronic that you will openly slate a company you’re invested in on a public forum. if you want to see some of your big losses returned then this tactic appears to make zero sense, especially to someone of your “supposed” previous career experience.

maybe that’s not the whole story though… effectively you’re either still invested in agl and a complete fool, or you have already sold and are bitterly ****ging off the company and can’t bear to see any sign of success. whatever it is we have to endure your miserable posts due to you making poor investment decisions in the past.

Quick question FeverTree. You seem bitterly unhappy with your investment. Why don't you just sell up?

That was yesterday Digger.

Interesting to see who is also attending the Boston DDR Summit (Post on Twitter):

"Nice to see #AGL will be rubbing shoulders with delegates from Astra Zeneca, Novartis, Pfizer et al at the Boston DDR Inhibitors Summit at the end of the month.

ANGLE certainly seem to be approaching 2024 with a marketing focussed spring in their step.

https://ddr-inhibitors-summit.com/program/full-event-guide/ "

https://x.com/RedditDeluxe/status/1745469586173030874?s=20

Blimey, the critics of AGL are very vocal today. The time and effort required to keep posting on a stock you have no stake in. Don't you have jobs to go to? Seriously? lol

Sangi,

The purpose of this board is to post relevant news about AGL and discuss the company in a constructive informative manner.

AGL’s attendance at the DDR summit is new news and demonstrates more signs proactivity from the BOD and a commercial focus.

This board has been full of inane dross recently so I thought I’d post some actual news.

Agreed NikNak, let’s stick to looking at what the company are now doing and are planning.

No response to my previous post regarding an actual material piece of news:

DDR Inhibitor Summit in BostonToday 10:05

Just seen this post on Twitter. Very positive indeed. Before TwoGood tries to negatively spin it, it’s Boston Massachusetts in the USA… Not Boston Lincolnshire!

“It would seem #AGL are taking the commercialisation bull by the horns and are pitching at the DDR Inhibitors Summit in Boston.

With recent big news and the @proactive_UK One2One Forum this evening at 6pm, ANGLE are very much on the front foot in 2024!

ddr-inhibitors-summit.com“

https://x.com/redditdeluxe/status/1745385829973770410?s=46&t=IHEn1TE0c7FNFBktt6H8XQ

Just seen this post on Twitter. Very positive indeed. Before TwoGood tries to negatively spin it, it’s Boston Massachusetts in the USA… Not Boston Lincolnshire!

“It would seem #AGL are taking the commercialisation bull by the horns and are pitching at the DDR Inhibitors Summit in Boston.

With recent big news and the @proactive_UK One2One Forum this evening at 6pm, ANGLE are very much on the front foot in 2024!

ddr-inhibitors-summit.com“

https://x.com/redditdeluxe/status/1745385829973770410?s=46&t=IHEn1TE0c7FNFBktt6H8XQ

Sangi, Bantham,

It all comes down to timescales. Most investors in todays market see a longterm hold as a week or two, couple of months max. Many are left disappointed if the price doesn’t react instantly.

All of my biggest wins have come from observing a stock over a period on time, lots of research and buying at (what I hope is) the lows and waiting patiently. Then of course exiting at (hopefully) the top. I managed this at i3e from 4p to 30p but it took 20 months to come to fruition.

To be honest this board isn’t offering anything useful to me, or anyone else, as an investor aside from mild amusement. At the end of the day, AGL will either keep getting contract wins and earn more money in ever increasing amounts, or it won’t and it’ll stagnate and eventually fizzle out (which would be a great shame for cancer research and long term holders)

I bought in at 11p in November with the hope that the former would happen and as yet I’ve been very happy with the progress being made. Positive study results, a contract win, product launches, doubled share price, Berenberg broker target of 120p and the company very much on the front foot targeting more commercial opportunities. So long may it continue!

Bought some more on this morning’s dip. Traders impatience is an investors opportunity. TR1 level within reach.

Good luck to all genuine holders new and old.

6pm UK time Paz

Initially more deals with large pharma's (or a huge one) and/or seeing the current Eisai pilot study blossom into an ongoing expansive, lucrative deal.

Nice to see the outstanding studies come back soon (this quarter too)